SCHEMBL25055554

SCHEMBL25055554

CC(=O)N1CCC2(CC1)SCCN2C(C)=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
USP2 O75604 2/20 0.36
ADRA2C P18825 1/20 0.35
KDM4E B2RXH2 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ALDH1A1 P00352 4/20 0.35
CYP2C19 P33261 3/20 0.35
MAPK1 P28482 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CYP2C9 P11712 4/20 0.34
TSHR P16473 3/20 0.34
CYP2D6 P10635 3/20 0.33
CYP3A4 P08684 3/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 2/20 0.33
EPHX2 P34913 2/20 0.33
ALOX12 P18054 1/20 0.33
HIF1A Q16665 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25055607 0.89 ALDH1A1 (0.33) CYP1A2TDP1USP2ADRA2CSMN1; SMN2
SCHEMBL25055543 0.85 PIK3CD (0.34) CYP1A2TDP1USP2ADRA2CKDM4E
SCHEMBL25055430 0.85 ADRA2C (0.35) CYP1A2TDP1USP2ADRA2CKDM4E
SCHEMBL25055494 0.85 ADRA2C (0.35) ADRA2CALDH1A1MEN1KMT2ACYP3A4
SCHEMBL25055498 0.85 ADRA2C (0.32) ADRA2C
SCHEMBL25055618 0.83 SMN1; SMN2 (0.38) CYP1A2TDP1ADRA2CKDM4ESMN1; SMN2
SCHEMBL25055524 0.82 ADRA2C (0.39) TDP1USP2ADRA2CKDM4EALDH1A1
SCHEMBL25055728 0.81 CYP1A2 (0.42) CYP1A2TDP1USP2KDM4ESMN1; SMN2
SCHEMBL25055529 0.81 DPP4 (0.35) ADRA2C
SCHEMBL25055435 0.80 ADRA2C (0.54) CYP1A2ADRA2CKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348493-A1 COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF BEIJING GREATWAY PHARMACEUTICAL TECHNOLOGY CO. LTD. (CN) 2023-11-02 US disclosed
US-20230348493-A1 COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF BEIJING GREATWAY PHARMACEUTICAL TECHNOLOGY CO. LTD. (CN) 2023-11-02 US disclosed
EP-4137496-A1 COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Beijing Greatway Pharmaceutical Technology Co., Ltd. (CN) 2023-02-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348493-A1 COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF GRIN1, GRIN3A, GRIN2C CYP1A2 3272/4885TDP1 1519/4885USP2 4692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.